Home Newsfeeds Chardan Capital Downgrades Oncorus to Neutral

Chardan Capital Downgrades Oncorus to Neutral

Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data In Webinar With Key Opinion Leader Adnan Khattak

By Benzinga Newsdesk

November 6, 11:13 AM

EVX-01 is Evaxion's lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 results Principal investigator Professor Adnan

EVAX

DoorDash To $129? Here Are 5 Other Price Target Changes For Friday

By Lisa Levin

August 5, 7:23 AM

Citigroup raised the price target on DoorDash, Inc. (NYSE: DASH) from $118 to $129. However, Citigroup analyst Ronald Josey maintained DoorDash with a Buy. DoorDash shares jumped 10.5% to $89.91 in pre-market trading.

DASH